Phase II study of high-sensitivity genotyping of KRAS , NRAS , BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Saved in:
| Title: | Phase II study of high-sensitivity genotyping of KRAS , NRAS , BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. |
|---|---|
| Authors: | Santos, C1 (AUTHOR), Azuara, D2 (AUTHOR), Viéitez, J M3 (AUTHOR), Páez, D4 (AUTHOR), Falcó, E5 (AUTHOR), Élez, E6 (AUTHOR), López-López, C7 (AUTHOR), Valladares, M8 (AUTHOR), Robles-Díaz, L9 (AUTHOR), García-Alfonso, P10 (AUTHOR), Bugés, C11 (AUTHOR), Durán, G12 (AUTHOR), Salud, A13 (AUTHOR), Navarro, V14 (AUTHOR), Capellá, G2 (AUTHOR), Aranda, E15 (AUTHOR), Salazar, R1 (AUTHOR) ramonsalazar@iconcologia.net |
| Source: | Annals of Oncology. May2019, Vol. 30 Issue 5, p796-803. 8p. 4 Charts, 1 Graph. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz082 |
